Reviva Pharmaceuticals (NASDAQ:RVPH) Trading Down 3.5% – Should You Sell?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)’s share price traded down 3.5% during mid-day trading on Wednesday . The stock traded as low as $1.09 and last traded at $1.09. 376,213 shares were traded during mid-day trading, a decline of 65% from the average session volume of 1,068,293 shares. The stock had previously closed at $1.13.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RVPH. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 target price on the stock. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Friday, January 10th. HC Wainwright lowered their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, January 21st. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Reviva Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $11.40.

Reviva Pharmaceuticals Stock Performance

The firm has a market cap of $33.78 million, a P/E ratio of -0.91 and a beta of -0.09. The firm’s fifty day simple moving average is $1.53 and its 200 day simple moving average is $1.47.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RVPH. Geode Capital Management LLC boosted its position in shares of Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after acquiring an additional 42,376 shares during the last quarter. EMC Capital Management grew its stake in shares of Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after buying an additional 26,134 shares in the last quarter. Drive Wealth Management LLC purchased a new stake in shares of Reviva Pharmaceuticals during the 4th quarter valued at about $36,000. Ameriprise Financial Inc. bought a new position in shares of Reviva Pharmaceuticals in the 4th quarter valued at about $84,000. Finally, Tang Capital Management LLC bought a new stake in Reviva Pharmaceuticals during the fourth quarter worth approximately $308,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.